Skip to content 
Search

Latest Stories

Novartis to acquire Medicines Company for £7.5bn 

SWISS pharmaceuticals giant Novartis announced over the weekend it would dish out $9.7 billion or £7.5bn to acquire US firm Medicines Company, in a move aimed at boosting its cardiovascular treatment portfolio.

Novartis said Sunday (24) it had agreed to pay $85 per Medicines Co. share, which was 41 per cent over the US company's closing price on Friday.


The move will mark the latest in a line of acquisitions aimed at enhancing the Swiss company's stable of cutting-edge drugs to treat things like cancer.

In snapping up Medicines Co., the pharma giant said it will lay its hands on a promising cholesterol drug called inclisiran, described by company chief Vas Narasimhan as a "potentially transformational medicine".

Inclisiran, which recently completed its phase III study, fights "bad" LDL cholesterol in patients with atherosclerosis, or plaque buildup in their arteries.

The drug, which requires far fewer annual injections than the products currently on the market, is based on RNA interference therapy.

This is a natural phenomenon used to silence specific genes that produce harmful or diseased proteins, whose discovery in the late 1990s earned Craig Mello and Andrew Fire the 2006 Nobel Medicine Prize.

Such therapy is increasingly being used for a range of conditions. The Medicine Co's drug specifically blocks the liver from making a particular enzyme, PCSK9, which in turn lowers the production of low-density lipoprotein.

Medicines Co has said it plans to request regulatory approval in the US by the end of the year, and in Europe in early 2020.

Overall sales of anti-cholesterol treatments are on average rising 11 per cent annually and are expected to reach $17.7bn by 2024, according to numbers from analysis firm EvaluatePharma.

High cholesterol is a key factor in coronary artery disease, the most common kind of heart disease and the number one killer of men and women worldwide, according to the World Health Organization.

If the transaction is completed, inclisiran will be added to Novartis's current cardiovascular products, including its heart-failure treatment Entresto, which saw its sales soar 61 per cent year on year to $430 million during the third quarter this year.

"Novartis has a longstanding history of delivering breakthrough cardiovascular treatments for patients, and I am very excited about the opportunity to add inclisiran to our cardiovascular portfolio," Marie-France Tschudin, president of Novartis Pharmaceutical, said in a statement.

Analysts with Jefferies hailed the move, saying there was a "clear strategic rationale" for the acquisition, and for "bolstering Novartis’ cardiovascular franchise, notably leveraging Entresto."

Novartis said it planned to pay for the acquisition with "available cash and short- and long-term borrowings."

The acquisition, which still needs a green light from antitrust authorities, is expected to be finalised during the first quarter of 2020.

(AFP)

More For You

Bangladesh seeks US deal to shield garment industry from tariffs

Workers are engaged at their sewing stations in a garment factory in Savar, on the outskirts of Dhaka, on April 9, 2025. (Photo by MUNIR UZ ZAMAN/AFP via Getty Images)

Bangladesh seeks US deal to shield garment industry from tariffs

BANGLADESH, the world's second-biggest garment manufacturer, aims to strike a trade deal with the US before Donald Trump's punishing tariffs kick in next week, said the country's top commerce official.

Dhaka is proposing to buy Boeing planes and boost imports of US wheat, cotton and oil in a bid to reduce the trade deficit, which Trump used as the reason for imposing painful levies in his "Liberation Day" announcement.

Keep ReadingShow less
UK business district
The Canary Wharf business district including global financial institutions in London.
Getty Images

Bond yields ease following Starmer’s support for Reeves

THE COST of UK government borrowing fell on Thursday, partially reversing the rise seen after Chancellor Rachel Reeves became emotional during Prime Minister’s Questions.

The yield on 10-year government bonds dropped to 4.55 per cent, down from 4.61 per cent the previous day. The pound also recovered slightly to $1.3668 (around £1.00), though it did not regain all its earlier losses.

Keep ReadingShow less
modi-trump-getty
Modi shakes hands with Trump before a meeting at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)
Getty Images

Indian exporters watch closely as Trump says trade deal with India likely

THE US could reach a trade deal with India that would help American companies compete more easily in the Indian market and reduce tariff rates, President Donald Trump said on Tuesday. However, he cast doubt on a similar deal with Japan.

Speaking to reporters on Air Force One, Trump said he believed India was ready to lower trade barriers, potentially paving the way for an agreement that would avoid the 26 per cent tariff rate he had announced on April 2 and paused until July 9.

Keep ReadingShow less
Kolhapuri sandal sales surge in India post Prada controversy

Customers shop for 'Kolhapuri' sandals, an Indian ethnic footwear, at a store in New Delhi, India, June 27, 2025. REUTERS/Adnan Abidi

Kolhapuri sandal sales surge in India post Prada controversy

INDIAN footwear sellers and artisans are tapping into nationalist pride stoked by the Prada 'sandal scandal' in a bid to boost sales of ethnic slippers with history dating back to the 12th century, raising hopes of reviving a struggling craft.

Sales are surging over the past week for the 'Kolhapuri' sandals that have garnered global attention after Prada sparked a controversy by showcasing similar designs in Milan, without initially crediting the footwear's origins.

Keep ReadingShow less
UK business district
The Canary Wharf business district including global financial institutions in London.
Getty Images

Economy grew 0.7 per cent in Q1 2025, fastest in a year

THE UK economy expanded at its fastest pace in a year during the first quarter of 2025, driven by a rise in home purchases ahead of a tax deadline and higher manufacturing output before the introduction of new US import tariffs.

Gross domestic product rose by 0.7 per cent in the January-to-March period, the Office for National Statistics (ONS) said, confirming its earlier estimate. This was the strongest quarterly growth since the first quarter of 2024.

Keep ReadingShow less